Cancer: A tumour gene's fatal flaws Export

by: Julian Downward

Nature, Vol. 462, No. 7269. (04 November 2009), pp. 44-45.

[Posts]

View FullText article

DOI, Nature, Rent at DeepDyve

renatomilani's tags for this article

cancer nf-kb ras

Reviews [Write a review of this article]

Find related articles from these CiteULike users

renatomilani, tonamswish

Find related articles with these CiteULike tags

cancer, lung_adenocarcinoma, nfkb, nf-kb, p53, ras, review

Abstract

Mutations in RAS genes are common in human tumours, but RAS has proved impossible to target with drugs. Its associated NF-B signalling pathway, however, may turn out to be this tumour gene's Achilles heel. RAS is one of the most commonly mutated gene families in human cancers — one of its three members (KRAS, HRAS and NRAS) is mutated in about 20% of human tumours. Attempts to target mutant RAS proteins directly with small-molecule inhibitors have so far proved unsuccessful, so there has been considerable interest in finding signalling pathways that function downstream of RAS and whose blockade might be selectively toxic to tumour cells.

@article{citeulike:6070879, abstract = {Mutations in RAS genes are common in human tumours, but RAS has proved impossible to target with drugs. Its associated NF-B signalling pathway, however, may turn out to be this tumour gene's Achilles heel. RAS is one of the most commonly mutated gene families in human cancers — one of its three members (KRAS, HRAS and NRAS) is mutated in about 20\% of human tumours. Attempts to target mutant RAS proteins directly with small-molecule inhibitors have so far proved unsuccessful, so there has been considerable interest in finding signalling pathways that function downstream of RAS and whose blockade might be selectively toxic to tumour cells.}, author = {Downward, Julian}, citeulike-article-id = {6070879}, citeulike-linkout-0 = {http://dx.doi.org/10.1038/462044a}, citeulike-linkout-1 = {http://dx.doi.org/10.1038/462044a}, day = {04}, doi = {10.1038/462044a}, issn = {0028-0836}, journal = {Nature}, keywords = {cancer, nf-kb, ras}, month = {November}, number = {7269}, pages = {44--45}, posted-at = {2009-11-05 21:02:08}, priority = {2}, publisher = {Nature Publishing Group}, title = {Cancer: A tumour gene's fatal flaws}, url = {http://dx.doi.org/10.1038/462044a}, volume = {462}, year = {2009} }

RIS record

TY - JOUR ID - citeulike:6070879 L3 - citeulike-article-id:6070879 N2 - Mutations in RAS genes are common in human tumours, but RAS has proved impossible to target with drugs. Its associated NF-B signalling pathway, however, may turn out to be this tumour gene's Achilles heel. RAS is one of the most commonly mutated gene families in human cancers — one of its three members (KRAS, HRAS and NRAS) is mutated in about 20% of human tumours. Attempts to target mutant RAS proteins directly with small-molecule inhibitors have so far proved unsuccessful, so there has been considerable interest in finding signalling pathways that function downstream of RAS and whose blockade might be selectively toxic to tumour cells. IS - 7269 JF - Nature SN - 0028-0836 EP - 45 TI - Cancer: A tumour gene's fatal flaws PB - Nature Publishing Group VL - 462 SP - 44 KW - cancer KW - nf-kb KW - ras AU - Downward, Julian PY - 2009/11/04/ UR - http://dx.doi.org/10.1038/462044a ER -

Cancer: A tumour gene's fatal flaws Export

Citation Format